Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ZYME

Zymeworks Inc.

Healthcare | Biotechnology

No licensed closing price on file for ZYME. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.02

Zymeworks Inc. (NASDAQ: ZYME) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 08:28 UTC.

What Zymeworks Inc. does

Zymeworks is a biotechnology company that develops multifunctional biotherapeutics to treat cancer, inflammation, and autoimmune disease. The company pursues a strategy combining internal drug discovery with strategic partnerships and acquisitions to build a portfolio of licensed healthcare assets and generate milestone and royalty revenues. The company leverages proprietary technology platforms in multispecific antibody therapeutics and antibody-drug conjugates to create novel treatments while sharing development risks through partnerships.

Summarized from Zymeworks Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.02

Revenue, margins & earnings

FY2021: net loss $212M on revenue $27M$27MFY2021FY2022 Net income: $124MFY2022 Taxes & interest: $6MFY2022 Operating costs: $282M$412MFY2022FY2023: net loss $119M on revenue $76M$76MFY2023FY2024: net loss $123M on revenue $76M$76MFY2024FY2025: net loss $81M on revenue $106M$106MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-09
  • 2026-10-09EVP, Head of R&DOption exercise37,037—
  • 2026-10-09EVP, Head of R&DSale-13,832$357.6K
  • 2026-10-09EVP, Head of R&DRestricted Stock UnitOption exercise-37,037—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Zymeworks Inc. do?

Zymeworks is a biotechnology company that develops multifunctional biotherapeutics to treat cancer, inflammation, and autoimmune disease.

When did ZYME last file with the SEC?

Zymeworks Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 08:28 UTC. This page is also available as JSON at /api/data?ticker=ZYME and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ZYME and 5,000+ tickers.

Create a free account — keep ZYME
For your agent
GET /api/data?ticker=ZYME

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt